Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase.
Munir S, Larsen SK, Iversen TZ, Donia M, Klausen TW, Svane IM, Straten PT, Andersen MH. Munir S, et al. Among authors: larsen sk. PLoS One. 2012;7(4):e34568. doi: 10.1371/journal.pone.0034568. Epub 2012 Apr 23. PLoS One. 2012. PMID: 22539948 Free PMC article.
Broadening the repertoire of melanoma-associated T-cell epitopes.
Frøsig TM, Lyngaa R, Met Ö, Larsen SK, Donia M, Svane IM, Thor Straten P, Hadrup SR. Frøsig TM, et al. Among authors: larsen sk. Cancer Immunol Immunother. 2015 May;64(5):609-20. doi: 10.1007/s00262-015-1664-x. Epub 2015 Feb 18. Cancer Immunol Immunother. 2015. PMID: 25854582 Free PMC article.
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, Zeyher C, Gouttefangeas C, Thomsen BM, Holm B, Thor Straten P, Mellemgaard A, Andersen MH, Svane IM. Iversen TZ, et al. Among authors: larsen sk. Clin Cancer Res. 2014 Jan 1;20(1):221-32. doi: 10.1158/1078-0432.CCR-13-1560. Epub 2013 Nov 11. Clin Cancer Res. 2014. PMID: 24218513 Clinical Trial.
Spontaneous presence of FOXO3-specific T cells in cancer patients.
Larsen SK, Ahmad SM, Idorn M, Met Ö, Martinenaite E, Svane IM, Straten PT, Andersen MH. Larsen SK, et al. Oncoimmunology. 2014 Nov 14;3(8):e953411. doi: 10.4161/21624011.2014.953411. eCollection 2014. Oncoimmunology. 2014. PMID: 25960934 Free PMC article.
CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment.
Martinenaite E, Munir Ahmad S, Hansen M, Met Ö, Westergaard MW, Larsen SK, Klausen TW, Donia M, Svane IM, Andersen MH. Martinenaite E, et al. Among authors: larsen sk. Oncoimmunology. 2016 Sep 30;5(11):e1238541. doi: 10.1080/2162402X.2016.1238541. eCollection 2016. Oncoimmunology. 2016. PMID: 27999757 Free PMC article.
29 results